For years, patients with Cystic Fibrosis (CF) were able to only treat the symptoms of the disease, but advancements over the last decade have made it possible to partially correct the genetic mutation which causes the disease. Treatment for this disease has long been complex due to the number of organs affected by the mutation, but these new modulator therapies add another level of complexity due to the large yearly cost of $300,000. While approvals for the drugs are reaching more age groups in many countries, ease of access still varies due to the reimbursement deals or prescription coverage available in each country.